ENZN
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals, Inc. (ENZN) is rated D+ (1.8/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Value (C+); its weakest is Momentum (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2025-03-31 | C+ (2.6) | C+ (2.5) | D+ (1.7) | D- (0.8) | D+ (1.5) | D+ (1.8) |
| 2024-06-30 | F (0.3) | C+ (2.5) | C- (1.9) | D- (0.8) | D (1.5) | D (1.4) |